Next Article in Journal
Unraveling the Relationship of Asthma and COVID-19
Next Article in Special Issue
Precision Medicine in Aortic Anastomosis: A Numerical and Experimental Study of a Novel Double-Sided Needle
Previous Article in Journal
Predictive Model for High Coronary Artery Calcium Score in Young Patients with Non-Dialysis Chronic Kidney Disease
Previous Article in Special Issue
The Potential of Gamma Secretase as a Therapeutic Target for Cardiac Diseases
Review

The Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases

1
Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA
2
Department of Mathematical Sciences, University of Delaware, Newark, DE 19716, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Elizabeth Vafiadaki, Despina Sanoudou and Irene C. Turnbull
J. Pers. Med. 2021, 11(12), 1373; https://doi.org/10.3390/jpm11121373
Received: 7 November 2021 / Revised: 9 December 2021 / Accepted: 13 December 2021 / Published: 16 December 2021
(This article belongs to the Special Issue Therapeutic Targets and Personalized Medicine in Cardiac Disease)
Heat shock protein 90 (Hsp90) is a molecular chaperone that interacts with up to 10% of the proteome. The extensive involvement in protein folding and regulation of protein stability within cells makes Hsp90 an attractive therapeutic target to correct multiple dysfunctions. Many of the clients of Hsp90 are found in pathways known to be pathogenic in the heart, ranging from transforming growth factor β (TGF-β) and mitogen activated kinase (MAPK) signaling to tumor necrosis factor α (TNFα), Gs and Gq g-protein coupled receptor (GPCR) and calcium (Ca2+) signaling. These pathways can therefore be targeted through modulation of Hsp90 activity. The activity of Hsp90 can be targeted through small-molecule inhibition. Small-molecule inhibitors of Hsp90 have been found to be cardiotoxic in some cases however. In this regard, specific targeting of Hsp90 by modulation of post-translational modifications (PTMs) emerges as an attractive strategy. In this review, we aim to address how Hsp90 functions, where Hsp90 interacts within pathological pathways, and current knowledge of small molecules and PTMs known to modulate Hsp90 activity and their potential as therapeutics in cardiac diseases. View Full-Text
Keywords: Hsp90; fibrosis; hypertrophy; cardiomyopathy; heart failure; HF; signal transduction Hsp90; fibrosis; hypertrophy; cardiomyopathy; heart failure; HF; signal transduction
Show Figures

Graphical abstract

MDPI and ACS Style

Roberts, R.J.; Hallee, L.; Lam, C.K. The Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases. J. Pers. Med. 2021, 11, 1373. https://doi.org/10.3390/jpm11121373

AMA Style

Roberts RJ, Hallee L, Lam CK. The Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases. Journal of Personalized Medicine. 2021; 11(12):1373. https://doi.org/10.3390/jpm11121373

Chicago/Turabian Style

Roberts, Richard J., Logan Hallee, and Chi K. Lam. 2021. "The Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases" Journal of Personalized Medicine 11, no. 12: 1373. https://doi.org/10.3390/jpm11121373

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop